What is the recommended management for herpes labialis (cold sores)?

Management of Herpes Labialis

For episodic treatment of herpes labialis, initiate oral antiviral therapy with either valaciclovir 2g twice daily for 1 day or famciclovir 1500mg as a single dose at the first sign of prodromal symptoms or within 48 hours of lesion onset. 1

Episodic Treatment Approach

First-Line: Short-Course Oral Antivirals

The evidence strongly supports high-dose, short-course oral antiviral regimens as the most effective episodic treatment:

• Valaciclovir: 2g twice daily for 1 day significantly reduces median episode duration (4.0-5.0 days vs 5.0-6.2 days with placebo, p<0.001) 1
• Famciclovir: 1500mg single dose reduces median healing time of primary lesions (4.4 days vs 6.2 days with placebo, p<0.001) 1
• Aciclovir: 400mg twice daily shows reduced recurrence (RR 0.26,95% CI 0.13-0.51), though requires more frequent dosing 2

Critical timing consideration: Treatment must begin during the prodromal stage or within 48 hours of lesion onset to achieve optimal results 3. Patient-initiated therapy at first symptom recognition is essential for maximum efficacy 1.

Oral vs Topical Therapy

Oral antiviral agents are superior to topical therapy for episodic treatment 3. Topical antivirals (5% aciclovir cream, 1% penciclovir cream) show minimal to no preventive effect, with moderate quality evidence demonstrating topical aciclovir has little impact on preventing HSL recurrence (pooled RR 0.91,95% CI 0.48-1.72) 2.

Advantages of Short-Course Regimens

The single-day or 1-2 day regimens with valaciclovir and famciclovir offer:

• Greater convenience and treatment adherence
• Cost-effectiveness compared to traditional 5-7 day courses 4
• Better oral bioavailability than aciclovir 3
• Reduced treatment burden while maintaining efficacy 1

Chronic Suppressive Therapy

For patients with severe or frequent recurrences (≥6 episodes per year), initiate long-term oral antiviral suppression 3.

Effective suppressive regimens include:

• Aciclovir: 400mg twice daily for 4 months reduces clinical recurrences by 53% (p=0.009) and extends time to recurrence (118 days vs 46 days with placebo, p=0.05) 1
• Valaciclovir: 500mg once daily significantly increases time to recurrence (13.1 weeks vs 9.6 weeks with placebo, p=0.016) and keeps 60% of patients recurrence-free vs 38% with placebo 1

Long-term suppressive regimens demonstrate greater efficacy than episodic treatment for reducing overall HSL incidence (difference of -0.10 episodes per month, 95% CI -0.16 to -0.05) 2.

Prevention Strategies

Trigger-Based Prevention

For patients with known triggers (UV exposure, sunlight), initiate short-term oral antiviral prophylaxis before exposure 2, 5:

• Aciclovir 400mg twice daily started 12 hours before UV exposure reduces lesion occurrence (7% vs 26% with placebo) 1
• Evidence for sunscreen protection is mixed: effective under experimental UV conditions but inconsistent with natural sunlight exposure 2, 5

Safety Profile

All three oral antivirals (aciclovir, valaciclovir, famciclovir) demonstrate excellent safety with minimal adverse events 1:

• Headache and nausea occur in <10% and <4% of patients respectively
• Adverse event rates similar to placebo in most trials
• No serious adverse events reported in short-course regimens
• Moderate quality evidence confirms no increased risk with oral antiviral use 2

Common Pitfalls to Avoid

1. Delayed treatment initiation: Starting antivirals after 48 hours significantly reduces efficacy
2. Using topical antivirals for prevention: No evidence supports topical agents for preventing recurrent HSL 2
3. Underdosing: Traditional lower-dose, longer-duration regimens are less convenient without superior efficacy
4. Not considering suppressive therapy: Patients with frequent recurrences benefit substantially from daily suppression but often aren't offered this option

Access Considerations

The evidence supports reclassifying oral antivirals from prescription-only to pharmacy-controlled status for herpes labialis, allowing earlier patient-initiated treatment during the critical therapeutic window 1. This approach reduces healthcare burden while maintaining appropriate safeguards through pharmacist oversight and patient education.